Claudin 18.2 (CLDN18.2) is emerging as a new alternative for gastric cancer with a poor prognosis, and a development boom is brewing among global pharmaceutical companies. Various new drugs such as cell therapy drugs and bispecific antibodies have been put to the test in order to preoccupy this market, which is a communist communist country.

According to the Ministry of Food and Drug Safety on the 27th, three CLDN18.2 target new drugs have been approved for clinical trials this year alone. Two cases are early-stage (phase 1/2 and phase 1) clinical trials, and one case is a late-stage phase 3 clinical trial. CLDN18.2 is a protein mainly present on the surface of gastric cancer cells. It is also present i